Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

The recent development of assays that accurately quantify neurofilament light, a neuronal
cytoskeleton protein, in plasma has generated a vast literature supporting that it is a …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
the loss of upper and lower motor neurons. Presently, three FDA-approved drugs are …

Neuronal injury is a universal event that occurs in disease processes that affect both the
central and peripheral nervous systems. A blood biomarker linked to neuronal injury would …

According to the Geroscience concept that organismal aging and age-associated diseases
share the same basic molecular mechanisms, the identification of biomarkers of age that can …

Background Serum glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) are
putative non-amyloid blood-based biomarkers indicative of ongoing inflammatory and …

With the inexorable aging of the global populace, neurodegenerative diseases (NDs) like
Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) …

Significant progress has been made in understanding the pre-symptomatic phase of
amyotrophic lateral sclerosis. While much is still unknown, advances in other …

Increasing appreciation of the phenotypic and biological overlap between amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence …